# Bivalirudin

Drug · id `cardio:bivalirudin` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Angiomax

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

Bivalirudin is a direct thrombin inhibitor given by vein as an anticoagulant. The US label read lists one use: as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), including patients with heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS). The label says it binds thrombin directly and reversibly.

## Technical summary

RxNorm ingredient 60819; UNII TN9BEX005G. MeSH has no descriptor for bivalirudin (an exact-label lookup and a contains lookup on 2026-11-09 returned none), so no MeSH identifier is recorded. Classes: Direct Thrombin Inhibitor and Anti-coagulant (FDA established pharmacologic classes, RxClass). The label read is the Civica, Inc. label for bivalirudin for injection, application NDA020873 (the application of the brand product Angiomax), effective 2025-09-10 in openFDA. openFDA returned no brand-named Angiomax record. Other bivalirudin labels were not read. This page records label indications and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: People for whom the US label of bivalirudin for injection lists an indication: anticoagulation during percutaneous coronary intervention, including heparin-induced thrombocytopenia

Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The label passage read does not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passage read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of bivalirudin for injection, in the Civica, Inc. version dated 2025-09-10 in openFDA (application NDA020873), describes bivalirudin as a direct thrombin inhibitor and lists it for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), including patients with heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS).

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The label passage read does not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passage read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label has no boxed warning section in openFDA; contraindications, doses, interactions and other warnings were not read. The atlas has no page for heparin-induced thrombocytopenia, so no edge to it is recorded. Labels differ between sponsors and change over time. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for Bivalirudin for Injection, Civica, Inc. label (application NDA020873): indications and mechanism (Regulator, edition The openFDA drug label record for set id 19a4afc5-151d-4d3c-bfef-48aa8797d695 (manufacturer Civica, Inc., application NDA020873), returned on 2026-11-09. The label text is dated 2025-09-10 (effective\_time). An openFDA brand-name search for ANGIOMAX returned no record. Fourteen other bivalirudin labels (several sponsors, generic and 505(b)(2) products) were listed and not read.) <https://api.fda.gov/drug/label.json?search=set_id:%2219a4afc5-151d-4d3c-bfef-48aa8797d695%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE (highlights). Retrieved 2026-11-09T13:16:15Z. Source state: Current. Version fingerprint: f0c2c42a75f215c009acc029d902785ae6f38dd5fac72d6557571d71259a64d8.
     How it applies: Label passage quoted in the research quote table (LB-04).
  2. Background: openFDA drug label record for Bivalirudin for Injection, Civica, Inc. label (application NDA020873): indications and mechanism (Regulator, edition The openFDA drug label record for set id 19a4afc5-151d-4d3c-bfef-48aa8797d695 (manufacturer Civica, Inc., application NDA020873), returned on 2026-11-09. The label text is dated 2025-09-10 (effective\_time). An openFDA brand-name search for ANGIOMAX returned no record. Fourteen other bivalirudin labels (several sponsors, generic and 505(b)(2) products) were listed and not read.) <https://api.fda.gov/drug/label.json?search=set_id:%2219a4afc5-151d-4d3c-bfef-48aa8797d695%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:16:15Z. Source state: Current. Version fingerprint: f0c2c42a75f215c009acc029d902785ae6f38dd5fac72d6557571d71259a64d8.
     How it applies: Effective date of the label text read, 20250910.

## Connected pages

- The label describes bivalirudin as a direct thrombin inhibitor indicated for use as an anticoagulant; RxClass also lists the Anti-coagulant pharmacologic class: Anticoagulants (`cardio:anticoagulants`)
- FDA label lists use as an anticoagulant in patients undergoing percutaneous coronary intervention as an indication: Percutaneous coronary intervention (stents) (`cardio:pci`)
- Files under this front: Medicines (`cardio:front-medicines`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 3 registry products
- 13 registry trials

## Provenance

Content hash: cad976b70bd8828393afa360ab43693bca394a20e8f4d19c3984abe34930c1ae
Last substantive edit: 2026-11-09
Evidence last checked: 2026-11-09
